The stock of Boston Scientific Corporation (NYSE:BSX) is a huge mover today! About 4.05M shares traded hands. Boston Scientific Corporation (NYSE:BSX) has risen 32.95% since March 9, 2016 and is uptrending. It has outperformed by 25.54% the S&P500.
The move comes after 9 months positive chart setup for the $30.93B company. It was reported on Oct, 12 by Barchart.com. We have $30.56 PT which if reached, will make NYSE:BSX worth $9.59 billion more.
Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 26. They expect $0.27 earnings per share, up 12.50% or $0.03 from last year’s $0.24 per share. BSX’s profit will be $357.96 million for 21.60 P/E if the $0.27 EPS becomes a reality. After $0.27 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Boston Scientific Corporation (NYSE:BSX) Ratings Coverage
Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. Boston Scientific Corporation has been the topic of 29 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Benchmark maintained the shares of BSX in a report on Thursday, July 23 with “Buy” rating. Needham maintained the stock with “Buy” rating in Friday, July 29 report. The firm has “Buy” rating given on Thursday, June 9 by Guggenheim. Needham maintained the stock with “Buy” rating in Wednesday, October 28 report. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Outperform” rating by Credit Suisse on Monday, August 10. Needham upgraded Boston Scientific Corporation (NYSE:BSX) on Monday, September 28 to “Buy” rating. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by UBS on Tuesday, September 22. Wedbush maintained the stock with “Neutral” rating in Thursday, April 28 report. Goldman Sachs upgraded the stock to “Neutral” rating in Thursday, August 27 report. Raymond James downgraded the stock to “Strong Buy” rating in Monday, October 5 report.
According to Zacks Investment Research, “Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.”
Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.23, from 0.93 in 2016Q1. The ratio increased, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Lombard Odier Asset (Switzerland) last reported 400,000 shares in the company. Wealthfront Incorporated holds 0.01% or 20,731 shares in its portfolio. First Republic Invest last reported 0.03% of its portfolio in the stock. Piedmont Investment Ltd Com has 0% invested in the company for 306,038 shares. The Pennsylvania-based Vanguard Grp Inc has invested 0.12% in Boston Scientific Corporation (NYSE:BSX). New Mexico Educational Retirement Board accumulated 0.17% or 158,162 shares. Polar Cap Llp accumulated 0.29% or 650,000 shares. Davidson Kempner Management Ltd Partnership holds 375,000 shares or 0.39% of its portfolio. Hbk Investments Lp holds 0.02% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 104,719 shares. Decatur Inc accumulated 2.33% or 739,905 shares. Point72 Asset Management Lp last reported 0.3% of its portfolio in the stock. Aberdeen Asset Mngmt Public Ltd Company Uk last reported 0.08% of its portfolio in the stock. Pura Vida Invs Limited Liability Company last reported 1.84% of its portfolio in the stock. Citadel Llc holds 0.38% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 14.69M shares. State Street Corp owns 51.67 million shares or 0.13% of their US portfolio.
Insider Transactions: Since April 27, 2016, the stock had 0 buys, and 16 sales for $15.01 million net activity. Pratt Timothy A. sold $580,073 worth of stock or 24,074 shares. On Monday, May 2 the insider Mahoney Michael F sold $2.21M. On Tuesday, May 3 Fitzgerald Joseph Michael sold $1.74 million worth of the stock or 79,960 shares. Shares for $1.88 million were sold by Ballinger Kevin J.. The insider Dawkins Keith D sold $1.77 million. Phalen Michael P. also sold $841,050 worth of Boston Scientific Corporation (NYSE:BSX) shares. Another trade for 2,800 shares valued at $62,020 was made by Sorenson John Bradley on Wednesday, May 11.
More recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Professor Ian Meredith To Join Boston Scientific As Executive Vice President …” on October 10, 2016. Also Prnewswire.com published the news titled: “Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 …” on October 03, 2016. Prnewswire.com‘s news article titled: “Boston Scientific Receives CE Mark For LOTUS Edgeâ„¢ Valve System” with publication date: September 19, 2016 was also an interesting one.
BSX Company Profile
Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.